Leronlimab a humanized anti-CCR5 monoclonal antibody ameliorates hepatic fibrosis in two preclinical fibrosis mouse models
Have we seen this before?
I see Melissa Palmer and a couple other names on both abstracts. But also missing or different names.
But I couldnt find publication dates from back when the other one came out.
And I was too lazy to closely compare both.
But Im pretty sure they are different.
..."The antifibrotic effects observed in the CCl₄-induced liver fibrosis model further support the288
consistency of leronlimab’s effects across distinct etiologies of liver injury. The CCl₄ model is289
characterized by hepatocellular injury, inflammatory cytokine release, and progressive fibrosis290
and is widely used to assess antifibrotic interventions. In this model, leronlimab significantly291
reduced fibrosis area by Sirius red staining, despite no significant changes in serum ALT levels, a292
finding that parallels the observations in the STAM models"
https://www.biorxiv.org/content/10.64898/2026...l.pdf+html
Have we seen this before?
I see Melissa Palmer and a couple other names on both abstracts. But also missing or different names.
But I couldnt find publication dates from back when the other one came out.
And I was too lazy to closely compare both.
But Im pretty sure they are different.
..."The antifibrotic effects observed in the CCl₄-induced liver fibrosis model further support the288
consistency of leronlimab’s effects across distinct etiologies of liver injury. The CCl₄ model is289
characterized by hepatocellular injury, inflammatory cytokine release, and progressive fibrosis290
and is widely used to assess antifibrotic interventions. In this model, leronlimab significantly291
reduced fibrosis area by Sirius red staining, despite no significant changes in serum ALT levels, a292
finding that parallels the observations in the STAM models"
https://www.biorxiv.org/content/10.64898/2026...l.pdf+html
9
